MX2022015216A - Compuestos de pladienolida y su uso. - Google Patents

Compuestos de pladienolida y su uso.

Info

Publication number
MX2022015216A
MX2022015216A MX2022015216A MX2022015216A MX2022015216A MX 2022015216 A MX2022015216 A MX 2022015216A MX 2022015216 A MX2022015216 A MX 2022015216A MX 2022015216 A MX2022015216 A MX 2022015216A MX 2022015216 A MX2022015216 A MX 2022015216A
Authority
MX
Mexico
Prior art keywords
compounds
cancers
useful
methods
pladienolide
Prior art date
Application number
MX2022015216A
Other languages
English (en)
Inventor
Parcharee Tivitmahaisoon
Satoshi Nagao
Atsushi Endo
John Wang
Gregg F Keaney
Kazunobu Kira
Yoshihiko Kotake
Masayuki Miyano
Norio Murai
Guo Zhu Zheng
Nicholas C Gearhart
Xiang Liu
Kenzo Arai
Andrew Cook
Baudouin Gerard
Lisa A Marcaurelle
Marta Nevalainen
Ming-Hong Hao
Sudeep Prajapati
Touping Luo
Jason T Lowe
Sonobe Regina Mikie Kanada
Shelby Ellery
James Palacino
Dominic Reynolds
Morgan Welzel O''SHEA
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2022015216A publication Critical patent/MX2022015216A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción proporciona compuestos de pladienolida novedosos, composiciones farmacéuticas que contienen los compuestos, y métodos para usar los compuestos como agentes terapéuticos. Estos compuestos pueden ser útiles en el tratamiento de cánceres, particularmente cánceres en los que se sabe que son útiles los agentes que se dirigen al espliceosoma y las mutaciones en el mismo. También se proporcionan en el presente documento métodos para tratar cánceres mediante la administración de al menos un compuesto descrito en el presente documento y al menos una terapia adicional.
MX2022015216A 2018-04-09 2020-10-08 Compuestos de pladienolida y su uso. MX2022015216A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862655021P 2018-04-09 2018-04-09
US201862679653P 2018-06-01 2018-06-01
US201962814843P 2019-03-06 2019-03-06
US201962814838P 2019-03-06 2019-03-06

Publications (1)

Publication Number Publication Date
MX2022015216A true MX2022015216A (es) 2023-01-04

Family

ID=66248768

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020010606A MX2020010606A (es) 2018-04-09 2019-04-08 Compuestos de pladienolida y su uso.
MX2023009976A MX2023009976A (es) 2018-04-09 2020-10-08 Compuestos de pladienolida y su uso.
MX2022015216A MX2022015216A (es) 2018-04-09 2020-10-08 Compuestos de pladienolida y su uso.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020010606A MX2020010606A (es) 2018-04-09 2019-04-08 Compuestos de pladienolida y su uso.
MX2023009976A MX2023009976A (es) 2018-04-09 2020-10-08 Compuestos de pladienolida y su uso.

Country Status (18)

Country Link
US (1) US11926619B2 (es)
EP (1) EP3774759A2 (es)
JP (2) JP7335265B2 (es)
KR (1) KR20210006907A (es)
CN (1) CN113166091A (es)
AU (2) AU2019251096B2 (es)
BR (1) BR112020020792A2 (es)
CA (1) CA3096400A1 (es)
CL (3) CL2020002604A1 (es)
CO (1) CO2020013834A2 (es)
IL (3) IL277749B2 (es)
JO (2) JOP20200242A1 (es)
MX (3) MX2020010606A (es)
PE (1) PE20212327A1 (es)
PH (1) PH12020500666A1 (es)
SG (1) SG11202009906TA (es)
TW (1) TW201945351A (es)
WO (1) WO2019199667A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022098712A1 (en) 2020-11-04 2022-05-12 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
CN115414351B (zh) * 2022-09-19 2024-05-17 山东大学齐鲁医院 pladienolide B与PD-L1抗体组合在肿瘤免疫治疗领域的应用
WO2024101298A1 (ja) * 2022-11-07 2024-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 マクロライド化合物の製造方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
CA2235226A1 (en) 1995-11-10 1997-05-15 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
EP1792991A1 (en) 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
AU2003252299A1 (en) 2002-07-31 2004-02-16 Eisai Co., Ltd. Novel physiologically active substance
BR0313039A (pt) 2002-07-31 2005-08-09 Mercian Corp Composto, medicamento, composição farmacêutica, método para prevenir ou tratar uma doença contra a qual um controle da expressão do gene é eficaz, método para prevenir ou tratar uma doença contra a qual a supressão da produção de vegf é eficaz, método para prevenir ou tratar uma doença contra a qual uma inibição da angiogênese é eficaz, uso do composto, método para produzir um composto 9-desoxi 1107, linhagem streptomyces sp. a-1543 (ferm bp-8442), método de produzir um composto 6- desoxi, e linhagem a-1544 (ferm bp-8446) ou linhagem a-1545 (ferm bp-8447)
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
KR20050086873A (ko) 2002-11-29 2005-08-30 메루샹가부시키가이샤 매크로라이드계 화합물의 제조 방법
EP1705247A4 (en) 2003-11-27 2008-08-20 Mercian Corp DNA ACCOMPANYING HYDROXYLATION OF A MAKROLIDE COMPOUND
US20080280288A1 (en) * 2004-02-06 2008-11-13 Toshimitsu Uenaka Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug
WO2006009276A1 (ja) 2004-07-20 2006-01-26 Eisai R & D Management Co., Ltd. プラジエノライドの生合成に関与するポリペプチドをコードするｄｎａ
WO2007110705A2 (en) 2005-09-28 2007-10-04 Novimmune Sa Macrolide as inhibitors of mhc class ii
WO2007110704A2 (en) 2005-09-28 2007-10-04 Novimmune Sa Macrolide compositions as therapeutic agent
JPWO2007043621A1 (ja) 2005-10-13 2009-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドｂ及びプラジエノライドｄの全合成方法
WO2008020584A1 (fr) 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Préparation lyophilisée stable
JPWO2008093853A1 (ja) 2007-01-29 2010-05-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 マクロライド系化合物の固体およびその製造法並びにその医薬組成物
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
CN101730693A (zh) * 2007-07-06 2010-06-09 卫材R&D管理有限公司 大环内酯系化合物的制造方法及其制造中间体
WO2013148324A1 (en) 2012-03-26 2013-10-03 The Regents Of The University Of California Anti-cancer polyketide compounds
BR122022015975B1 (pt) 2012-05-15 2024-01-02 Bristol-Myers Squibb Company Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo
US20140275010A1 (en) 2013-03-12 2014-09-18 Guo Zhu Zheng Quaternary salts
TWI634115B (zh) * 2014-05-15 2018-09-01 Eisai R&D Management Co., Ltd. 普拉二烯內酯吡啶化合物及其使用方法
US20160009805A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
EP3910073B1 (en) 2015-09-01 2024-03-06 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants
KR20180083376A (ko) * 2015-11-18 2018-07-20 에자이 알앤드디 매니지먼트 가부시키가이샤 플라디에놀리드 피리딘 화합물의 고체 상태 형태 및 사용 방법
US11998544B2 (en) 2018-06-01 2024-06-04 Eisai R&D Management Co., Ltd. Methods of using splicing modulators

Also Published As

Publication number Publication date
US11926619B2 (en) 2024-03-12
JP2021521124A (ja) 2021-08-26
CA3096400A1 (en) 2019-10-17
JOP20200242A1 (ar) 2020-09-29
CL2022000458A1 (es) 2022-10-21
CL2020002604A1 (es) 2021-01-15
IL277749A (en) 2020-11-30
CO2020013834A2 (es) 2020-12-10
SG11202009906TA (en) 2020-11-27
IL303335A (en) 2023-07-01
AU2019251096A1 (en) 2020-11-26
EP3774759A2 (en) 2021-02-17
CN113166091A (zh) 2021-07-23
AU2023202358A1 (en) 2023-05-18
MX2023009976A (es) 2023-10-30
IL277749B2 (en) 2023-11-01
US20210163456A1 (en) 2021-06-03
IL277749B1 (en) 2023-07-01
PE20212327A1 (es) 2021-12-14
WO2019199667A2 (en) 2019-10-17
TW201945351A (zh) 2019-12-01
PH12020500666A1 (en) 2021-07-26
IL312725A (en) 2024-07-01
KR20210006907A (ko) 2021-01-19
MX2020010606A (es) 2021-01-15
JP7335265B2 (ja) 2023-08-29
BR112020020792A2 (pt) 2021-01-12
AU2019251096B2 (en) 2023-04-20
JP2023156456A (ja) 2023-10-24
JOP20200243A1 (ar) 2020-09-29
WO2019199667A3 (en) 2019-11-21
CL2023002549A1 (es) 2024-01-26

Similar Documents

Publication Publication Date Title
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12020500666A1 (en) Pladienolide compounds and their use
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
NZ729643A (en) Combination therapy for treating cancer
MX2016007351A (es) Terapia de combinacion para tratar cancer.
SG10201902664RA (en) Combination therapy for treating cancer
PH12016502249A1 (en) Pladienolide pyridine compounds and methods of use
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
WO2015035410A8 (en) Cancer therapy
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
EA202191415A1 (ru) Комбинированная терапия, включающая ингибитор krasg12c и одно или несколько дополнительных фармацевтически активных средств, для лечения видов рака
EA202091908A3 (ru) Комбинированная терапия для лечения онкологического заболевания